Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4269MR)

This product GTTS-WQ4269MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4269MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11559MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ12761MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ15317MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ48MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ1187MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ410MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ2948MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ8268MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW